PubMed Health⌕ Search

Biomedical subjects

E Marano

Publications and source records attributed to E Marano.

At least 37 records · Page 2Linked to original sources
PubMed1989

[Importance of a particular formula of soybean milk without S2 globulin, in the treatment of allergy to cow's milk proteins].

Replacing cow's milk with a soybean milk is one of the first measures which are commonly taken with babies suffering from cow's milk protein allergy. Unfortunately soybean can induce sensitization, too, with a variable percentage (ranging from 12 to 80%) according to the different Authors, due to the presence of allergenic proteins, among which the most important one seems to be S2 globulin. An excellent tolerability has been reported in a study carried out with 20 babies suffering from cow's milk protein allergy besides a good palatability of the product with a solution of symptoms in 87.3% of the cases. Only in 16.7% of the treated babies intolerance has been reported and therefore we can conclude that soybean milk has proved to be an excellent substitute of cow's milk in babies suffering from cow's milk protein allergy.

Child, Preschool↗
PubMed1989

Steroid-induced disappearance of primary central nervous system lymphoma. Clinical, neuroradiological and pathological findings.

A 73-year-old man presented a progressive neurologic syndrome with impairment of multiple cranial nerves, ataxia and limb weakness. Neuroradiological evaluation showed multiple supra and infratentorial lesions, which completely disappeared after steroid treatment on two occasions. These neuroradiological modifications were closely correlated with clinical picture and CSF findings. Post-mortem examination showed multifocal primary CNS immunoblastic large cell lymphoma. Immunohistochemistry showed that the tumor was of B-cell origin.

Aged↗
PubMed1988

Flunarizine in prophylaxis of childhood migraine. A double-blind, placebo-controlled, crossover study.

An 8-month, double-blind, placebo-controlled, crossover trial of flunarizine in the prophylaxis of migraine has been performed in 70 children. After 4 weeks of medication-free base-line observation, 35 children (group A) received flunarizine (5 mg/day) and 35 (group B) received placebo over a 12-week period. After a 4-week washout they crossed treatments for another 12 weeks. Sixty-three patients completed the trial. In both groups flunarizine significantly reduced the frequency and average duration of headache attacks. In group A efficacy was maintained after placebo crossover for the last 4 months of the study. Five subjects in group B stopped placebo because of ineffectiveness; two children in group A discontinued flunarizine treatment, one because of excessive daytime sedation and the other because therapy was ineffective. The main side effects were daytime sedation and weight gain. It is concluded that flunarizine is an effective drug for the treatment of childhood migraine. In a study of this length no serious side effects were discovered.

Child↗
PubMed1985

Flunarizine v. placebo in childhood migraine. A double-blind study.

Successful migraine prophylaxis with flunarizine has been reported in adults by several authors. We used flunarizine in a double-blind, placebo controlled, randomized trial in childhood migraine. Twenty-four children with classical or common migraine were followed by a 12-week flunarizine treatment period. Each patient took 5 mg/day of the drug before going to sleep. Twenty-four children with similar clinical characteristics were assigned to placebo treatment. Efficacy of flunarizine versus placebo was assessed on the basis of the reduction of headache frequency and duration. A statistical comparison was performed between values reported in the treatment period and those in the three months before. Children treated with flunarizine experienced a statistically significant reduction in headache (66%) and duration (51%). These results were statistically superior to those observed in the placebo group. Sixteen patients on flunarizine therapy experienced an improvement of more than 50% of both parameters. We found flunarizine is an effective agent in children's migraine prophylaxis. Moreover it is suitable for the low incidence of mild side effects.

Calcium Channel Blockers↗
PubMed1984

Efficacy of baclofen in trigeminal neuralgia and some other painful conditions. A clinical trial.

Baclofen (beta-4-chlorophenyl-gamma-aminobutyric acid) shows analgesic properties in rats and resembles carbamazepine and phenytoin in its effects on the spinal trigeminal nucleus of cats. We have, therefore, conducted a clinical trial in 25 subjects, 16 suffering from trigeminal neuralgia, and 9 patients were affected by different painful conditions such as postherpetic neuralgia, tabes dorsalis, postarachnoid radiculitis. 5 of the former groups were refractory to or unable to tolerate carbamazepine. Baclofen has significantly exhibited analgesic efficacy: all groups, as a whole, were improved by 68.61%. These results substantiate that baclofen is useful in the treatment of trigeminal neuralgia and other painful conditions.

Adult↗
PubMed1983

Evidence for a dose-dependent effect in the sex-specific plasma prolactin response to naloxone in humans.

In attempt to ascertain if the sex specific plasma PRL response to naloxone, that we suggested in previous studies, was a dose dependent effect, 26 healthy volunteers were studied. They received naloxone 2 mg and 4.8 mg or a volume matched of saline i.v. as a bolus. Blood samples were collected and plasma PRL was measured by double antibody RIA. Naloxone, at dose of 2 mg, was able to decrease significantly plasma PRL levels in normally menstruating women (p less than 0.05 at 60 min.; p less than 0.01 at 120 min.), but not in post-menopausal ones and in men. In addition, the dose of 4.8 mg of the drug did not change plasma PRL in any group. These results suggest a dose-dependent effect in the sex specific PRL response to naloxone in humans.

Adult↗
PubMedDate not supplied

Prophylaxis of migraine attacks with a calcium-channel blocker: flunarizine versus methysergide.

In this study, flunarizine, a selective calcium-channel blocker, was employed in the prophylactic treatment of headache and was compared with methysergide in terms of efficacy. The trial was conducted with 104 patients (53 treated with flunarizine and 51 treated with methysergide) and lasted six months--one month of pretreatment and five months of therapy. Patients in both groups experienced a highly significant reduction in the number and duration of migraine attacks. Unlike those in the methysergide group, patients treated with flunarizine achieved a significant reduction in the intensity of attacks with very negligible side effects.

Adult↗